Filing Flows

Filing Flows › Companies › Harvard Bioscience › Cash flow

Harvard Bioscience cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$363K in Q2 2026 · −$1.1M over twelve months

Operating cash flow$325K
Capital spending−$688K
Free cash flow−$363K
Cash conversion cycle207 days

Analysis

In Q2 2026, Harvard Bioscience generated $325K of operating cash flow and spent $688K on capital projects, leaving free cash flow of −$363K. That is $3.0M less than in Q2 2025 ($2.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was $651K; the largest uses were net borrowing (+) / repaid (−) ($22.7M), capital spending ($1.8M), other investing ($713K); besides operations, cash came from other financing ($24.0M); the cash balance fell by $939K.

Operating cash flow was $325K against net income of −$2.9M. The largest differences: depreciation & amortization +$1.3M, prepaid and other assets +$781K, payables +$383K.

Its cash conversion cycle was 207 days (receivables 58 + inventory 200 − payables 52).

Free cash flow

Harvard Bioscience: free cash flow by quarterHarvard Bioscience: free cash flow by quarter−$1.7MQ3 2024$1.4MQ4 2024$2.5MQ1 2025$2.7MQ2 2025$877KQ3 2025−$545KQ4 2025−$1.1MQ1 2026−$363KQ2 2026
Operating cash flow less capital spending.
Harvard Bioscience: operating cash flow against capital spendingHarvard Bioscience: operating cash flow against capital spendingOperating cash flowCapital spending−$842K$880KQ3 2024$1.7M$301KQ4 2024$3.0M$513KQ1 2025$2.8M$89KQ2 2025$1.1M$207KQ3 2025−$96K$449KQ4 2025−$662K$426KQ1 2026$325K$688KQ2 2026
Latest (Q2 2026): Operating cash flow $325K, Capital spending $688K.

Capital allocation, year by year

Harvard Bioscience: where the cash came from (up) and went (down), by fiscal yearHarvard Bioscience: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow $1.3MFY2021: Shares issued $3.3MFY2021: Capital spending −$1.2M$4.6MFY2021FY2022: Operating cash flow $1.2MFY2022: Net borrowing −$1.8MFY2022: Shares issued $577KFY2022: Capital spending −$1.6M$1.7MFY2022FY2023: Operating cash flow $14.0MFY2023: Net borrowing −$10.5MFY2023: Shares issued $930KFY2023: Asset sales $512KFY2023: Capital spending −$1.8M$15.5MFY2023FY2024: Operating cash flow $1.4MFY2024: Net borrowing $227KFY2024: Shares issued $380KFY2024: Capital spending −$2.6M$2.0MFY2024FY2025: Operating cash flow $6.7MFY2025: Net borrowing $2.6MFY2025: Shares issued $47KFY2025: Capital spending −$1.3M$9.4MFY2025
Over these 5 years operating cash flow totalled $24.6M; the largest uses were net borrowing ($12.3M) and capital spending ($8.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$6.5M
Debt$36.7M
Net debt$30.2M

Harvard Bioscience's operations bring cash in ($651K over twelve months), and it spends more than that on capital projects: a gap of $1.1M funded from its $6.5M of cash and investments and from borrowing ($36.7M of debt). That is a choice to invest, not a cash runway running down.

Harvard Bioscience: debt maturities by year (FY2025)Harvard Bioscience: debt maturities by year (FY2025)$1.6MYear 2$6.5MYear 3$31.9MYear 4
Principal due in each year as disclosed in the annual report, against $6.5M of cash and investments now.

Where the cash came from and went

Harvard Bioscience: sources (+) and uses (−) of cash, Q2 2026Harvard Bioscience: sources (+) and uses (−) of cash, Q2 2026Capital spending−$688KCash drawn (+) / kept (−)$595KOperating cash flow$325KOther investing−$228KTaxes on employees’ shares−$36KExchange rates$34KOther financing−$2K
Harvard Bioscience: sources (+) and uses (−) of cash, TTM to Q2 2026Harvard Bioscience: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$24.0MNet borrowing (+) / repaid (−)−$22.7MCapital spending−$1.8MCash drawn (+) / kept (−)$939KOther investing−$713KOperating cash flow$651KExchange rates−$231KTaxes on employees’ shares−$147K

From profit to cash

Harvard Bioscience: net income to operating cash flow, Q2 2026Harvard Bioscience: net income to operating cash flow, Q2 2026Net income−$2.9MDepreciation & amortization$1.3MStock-based pay$380KReceivables$58KInventory−$184KPayables$383KDeferred revenue−$48KPrepaid and other assets$781KOperating cash flow$325K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20265820052207
Q1 20266622747247
Q4 20255520442216
Q3 20255423553236
Q2 20255723049238
Q1 20255921645230
Q4 20245221544223
Q3 20245325555254

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$325K−$688K——$595K−$363K
Q1 2026−$662K−$426K—$150K$1.5M−$1.1M
Q4 2025−$96K−$449K−$34.4M$1K−$1.8M−$545K
Q3 2025$1.1M−$207K−$1.0M—$625K$877K
Q2 2025$2.8M−$89K−$1.0M$46K−$1.9M$2.7M
Q1 2025$3.0M−$513K−$1.0M—−$1.4M$2.5M
Q4 2024$1.7M−$301K−$1.0M$161K$461K$1.4M
Q3 2024−$842K−$880K$2.2M$15K−$521K−$1.7M

Harvard Bioscience: income statement and cash flow

Harvard Bioscience, Q2 2026: revenue $22.7M (+11% year over year), operating margin -4.3%. The chart follows the revenue to costs, profit and cash.

Harvard Bioscience: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.